Bevacizumab and Glioblastoma: Past, Present, and Future Directions

@article{Kim2018BevacizumabAG,
  title={Bevacizumab and Glioblastoma: Past, Present, and Future Directions},
  author={Michelle M. Kim and Yoshie Umemura and Denise Leung},
  journal={The Cancer Journal},
  year={2018},
  volume={24},
  pages={180–186}
}
Abstract Glioblastoma (GBM) is the most common and lethal intracranial malignancy, with few advances in treatment over the last several decades. Much excitement surrounded the initial approval for bevacizumab for recurrent GBM, given the marked radiographic responses and improvement in progression-free survival observed in early studies. However, phase III studies have failed to demonstrate an overall survival advantage with the use of this agent. An overview of the mechanism of action and… Expand
Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial
TLDR
This biomarker sub-study attempted to identify novel biomarkers involved in cancer treatment response to bevacizumab and identified a gain in Chromosome 19 that was exclusive to the exceptional survivors. Expand
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery,Expand
Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity
TLDR
Using the invasion spectrum of a tumor sample is a novel tool to distinguish between histological subtypes, specifying the tumor grades or different prognostic groups, and these are crucial steps towards personalized oncotherapy. Expand
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
TLDR
Overall, bevacizumab is expected to remain a key agent in cancer therapy, both due to its established efficacy in approved indications and its promise as a partner in novel targeted combination treatments. Expand
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
TLDR
The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations, and key challenges, and examine promising approaches under preclinical development. Expand
Changes in the tumor microenvironment and treatment outcome in glioblastoma: A pilot study
TLDR
Differences in the TME in respect of T-cell population, M1 and M2 macrophage polarization status, and MDSC population following different treatments in a syngeneic model of GBM showed that changes in theTME-associated cells were dependent on the therapeutic agents and the T ME-targeting therapy improved the survival of the GBM bearing animals. Expand
Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study
TLDR
Differences in the TME in respect of T-cell population, M1 and M2 macrophage polarization status, and MDSC population following different treatments in a syngeneic model of GBM showed that changes in theTME-associated cells were dependent on the therapeutic agents, and the T ME-targeting therapy improved the survival of the GBM bearing animals. Expand
Integration of Molecular Analysis, Cutting-edge Mouse Genetic Models and Proton Therapy to Improve Outcomes for Glioma Patients
TLDR
This chapter describes the current state-of-the-art molecular analysis approaches, latest in glioma mouse modelling, and advances in the application of proton therapy treatment and research. Expand
Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields
TLDR
The present article reviews the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG and describes emerging treatments expected to improve the prospects of patients with HGG. Expand
Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective
TLDR
This review encompasses the recent advances of bio-computational in-silico modeling that have elicited the discovery of small molecule inhibitors and/or drugs against various therapeutic targets in glioma. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 92 REFERENCES
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
TLDR
This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS). Expand
Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
TLDR
Clinical results with bevacizumab for glioblastoma treatment to date, ongoing trials designed to address unanswered questions, current clinical indications based on existing data, neurosurgical implications of bevacszumab use in patients with gliOBlastoma, the current scientific understanding of the tumor response to short- and long-term bevazquezumab treatment, and future studies that will need to be undertaken to enable this treatment to fulfill its therapeutic promise. Expand
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
TLDR
Adding carboplatin resulted in more toxicity without additional clinical benefit, and clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies. Expand
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
TLDR
It is demonstrated that tumors assigned to the IGS-18 or "classical" subtype and treated with beva+CCNU showed a significant benefit in progression-free survival and a trend toward benefit in overall survival, whereas other subtypes did not exhibit such benefit. Expand
Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival
TLDR
The extent of edema relative to enhancing area may have a prognostic role specific to Grade III HGG, and area of enhancing tumor at baseline can stratify survival in patients with recurrent HGG treated with bevacizumab. Expand
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
TLDR
It is demonstrated that improved perfusion occurs only in a subset of patients in cediranib-containing regimens, and is associated with improved overall survival in these nGBM patients, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. Expand
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
TLDR
Treatment with bevacizumab and TMZ is feasible and well tolerated but did not improve PFS6 and median OS. Expand
Lomustine and Bevacizumab in Progressive Glioblastoma
TLDR
Despite somewhat prolonged progression‐free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with LOMustine alone in patients with progressive glioblastoma. Expand
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
  • T. Sandmann, R. Bourgon, +16 authors C. Bais
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
Retrospective analysis of AVAglio data suggests that patients with IDH1 wild-type proneural glioblastoma may derive an OS benefit from first-line bevacizumab treatment. Expand
Bevacizumab for recurrent malignant gliomas
TLDR
Combination therapy with bevacizumab and chemotherapy is well-tolerated and active against recurrent malignant gliomas and may alter the recurrence pattern of malignantgliomas by suppressing enhancing tumor recurrence more effectively than it suppresses nonenhancing, infiltrative tumor growth. Expand
...
1
2
3
4
5
...